georgeclerk
H.C. Wainwright downgraded Summit Therapeutics (SMMT) to Neutral from Buy, citing overhang from a new late-stage trial readout for sac-TMT, a lung cancer therapy developed by Merck (MRK) in partnership with Chinese company Kelun-Biotech.
According to an ASCO abstract on
